Latest news about Remus Pharmaceuticals
Remus Pharmaceuticals
960.00
-16.35(-1.67%)
Company Performance:
View Company Insights1D-1.67%
1M+3.35%
6M0.00%
1Y+41.60%
5Y-59.46%
More news about Remus Pharmaceuticals
21May 26
Remus Pharmaceuticals appoints Tapan Shah as Secretarial Auditor
Remus Pharmaceuticals Limited appointed Mr. Tapan Shah as Secretarial Auditor for FY 2026-2027 on May 20, 2026. The Board approved the appointment based on the Audit Committee's recommendation. Mr. Shah brings over two decades of experience in corporate and regulatory compliance.
21May 26
Remus Pharmaceuticals appoints Sharp & Tannan as Internal Auditor
Remus Pharmaceuticals Limited has appointed Sharp & Tannan Associates as its Internal Auditor for the financial year 2026-27. The Board of Directors approved the appointment on May 20, 2026, based on the Audit Committee's recommendation. The firm, established in 1934, brings extensive experience in internal audit and assurance services.
10Nov 25
Remus Pharmaceuticals Posts 34% Surge in H1 Net Profit, Revenue Soars 47%
Remus Pharmaceuticals, a key player in the Indian pharmaceutical sector, has announced robust financial results for the first half of the fiscal year. The company's consolidated revenue increased by 47% to ₹4,000.00 crore, while net profit rose by 34% to ₹175.00 crore compared to the same period last year. EBITDA grew by 27% to ₹269.00 crore. However, the EBITDA margin contracted by 110 basis points to 6.70% from 7.80% in the previous year.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Laurus Labs
Cipla
Dr Reddys Laboratories
Mankind Pharma
Aurobindo Pharma
Lupin
1,756.90
(-0.18%)
9,400.50
(+0.65%)
4,630.10
(-0.58%)
1,116.60
(-0.08%)
2,049.90
(+0.65%)
1,304.50
(+0.27%)
1,225.90
(+2.41%)
2,404.00
(+1.50%)
1,696.30
(+0.19%)
1,941.10
(-0.79%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
